Fas-mediated apoptosis in human prostatic carcinoma cell lines

Cancer Research

Volumn 57, Issue 9, 1997, Pages 1758-1768

  Rokhlin, Oskar W ^a,e   Bishop, Gail A ^b   Hostager, Bruce S ^b   Waldschmidt, Thomas J ^a   Sidorenko, Svetlana P ^c   Pavloff, Nadine ^d   Kiefer, Michael C ^d   Umansky, Samuil R ^d   Glover, Rebecca A ^a   Cohen, Michael B ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c Inst Exp Pathol Oncol R   (Ukraine)

^d LXR Biotechnology Inc   (United States)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; COMPLEMENTARY DNA; CYCLOHEXIMIDE; DNA FRAGMENT; FAS ANTIGEN; MONOCLONAL ANTIBODY; PHOSPHOTYROSINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION;

ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, CD40; ANTIGENS, CD95; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CELL DIVISION; CYCLOHEXIMIDE; DNA FRAGMENTATION; FLOW CYTOMETRY; HUMANS; MALE; PHOSPHOTYROSINE; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 14444279883     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Steller, H. Mechanisms and genes of cellular suicide. Science (Washington DC), 267: 1445-1449, 1995
2. Nagata, S., and Golstein, P. The Fas death factor. Science (Washington DC), 267: 1449-1456, 1995.
3. Tartaglia, L. A., Ayres, T. M., Wong, G. H., and Goeddel, D. V. A novel domain within the 55 kd TNF receptor signals cell death. Cell, 74: 845-853, 1993.
4. Itoh, N., and Nagata, S. A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. J. Biol. Chem., 268: 10932-10937, 1993.
5. Boldin, M. P., Mett, I. L., Varfolomeev, E. E., Chumakov, I., Chemer-Avni, Y., Camonis, J. H., and Wallach, D. Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J. Biol. Chem., 270: 387-391, 1995.
6. Chinnaiyan, A. M., O'Rourke, K., Tewari, M., and Dixit, V. M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell, 81: 505-512, 1995.
7. Boldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett, I. L., Camonis, J. H., and Wallach, D. A novel protein that interacts with the death domain of Fas/Apo1 contains a sequence motif related to the death domain. J. Biol. Chem., 270: 7795-7798, 1995.
8. Hsu, H., Xiong, J., and Goeddel, D. V. The TNF receptor 1-associated protein TRADD signals cell death and NF-kB activation. Cell, 81: 495-504, 1995.
9. Stanger, B. Z., Leder, P., Lee, T-H., Kim, E., and Seed, B. RIP: a novel protein containing a death domain that interacts with Fas/APO1 (CD95) in yeast and causes cell death. Cell, 81: 513-523, 1995.
10. Varfolomeev, E. E., Boldin, M. P., Goncharov, T. M., and Wallach, D. A potential mechanism of "cross-talk" between the p55 tumor necrosis factor receptor ans Fas/APO1: protein binding to the death domains of the two receptors also bind to each other. J. Exp. Med., 183: 1271-1275, 1996.
11. Tewari, M., and Dixit, V. M. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J. Biol. Chem., 270: 3255-3260, 1995.
12. Enari, M., Hug, H., and Nagata, S. Involvement of an ICE-like protease in Fasmediated apoptosis. Nature (Lond.)., 375: 78-81, 1995.
13. Los, M. Van de Craen, M., Penning, L. C., Schenk, H., Westendorp, M., Baeuerle, P. A., Droge, W., Kramer, P. H., Fiers, W., and K. Schulze-Osthoff, K. Requirement of an ICE/CED-3protease for Fas/APO-1-mediated apoptosis. Nature (Lond.)., 375: 81-83, 1995.
14. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell, 85: 803-815, 1996.
15. Mizio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Kramer, P. H., Peter, M. E., and Dixit, V. M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell, 85: 817-827, 1996.
16. Fraser, A., and G. Evan, G. A license to kill. Cell, 85: 781-784, 1996.
17. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer Statistics, 1996. CA Cancer J. Clin., 46: 5-28, 1996.
18. Kyprianou, N., English, H. F., and Isaacs, J. T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748-3753, 1990.
19. Sklar, G. N., Eddy, H. A., Jacobs, S. C., and Kyprianou, N. Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. J. Urol., 150: 1526-1532, 1993.
20. Furuya, Y., and Isaacs, J. T. Proliferation-dependent vs independent programmed cell death of prostatic cancer cells involves distinct gene regulation. Prostate, 25: 301-309, 1994.
21. Kyprianou, N. Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World J. Urol., 12: 299-303, 1994.
22. Kyprianou, N., Bains, A. K., and Jacobs, S. C. Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death. Prostate, 25: 66-75, 1994.
23. Young, C. Y. F., Murtha, P. E., and Zhang, J. Tumor-promoting phorbol ester-induced cell death and gene expression in a human prostate adenocarcinoma cell line. Oncol. Res., 6: 203-210, 1994.
24. Berchem, G. J., Bosseler. M., Sugars, L-V. Y., Voeller, H. J., Zeitlin, S., and Gelmann, E. P. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res., 55: 735-738, 1995.
25. Zhang, H., Hoang, T., Saeed, B., and Ng, S-C. Induction of apoptosis in prostatic tumor cell line DU145 by staurosporine, a potent inhibitor of protein kinases. Prostate, 29: 69-76, 1996.
26. Narayan, P., and Dahiya, R. Establishment and characterization of a human primary prostate adenocarcinoma cell line (ND-1). J. Urol., 148: 1000-1004, 1992.
27. Loop, S. M., Rozanski, T. A., and Ostenson, R. C. Human primary prostate tumor cell line, ALVA-31: a new model for studying the hormonal regulation of prostate tumor cell growth. Prostate, 22: 93-108, 1993.
28. Muraki, J., Addonizio, J. C., Choundhury, M. S., Fisher, J., Eshghi, M., Davidian, M. M., Shapiro, L. R., Wilmot, P. L., Nagamatsu, G. R., and Chiao, J. W. Establishment of new human prostatic cancer cell line (JCA-1). Urology, 36: 79-84, 1990.
29. Klaus, S. J., Sidorenko, S. P., and Clark, E. A. CD45 ligation induces programmed cell death in T and B lymphocytes. J. Immunol., 156: 2743-2753, 1996.
30. Borner, M. M., Myers, C. E., Sartor, O., Sei, Y., Toko, T., Trepel, J. B., and Schneider, E. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res., 55: 2122-2128, 1995.
31. Matzinger, P. The JAM test: a simple assay for DNA fragmentation and cell death. J. Immunol. Methods, 145: 185-192, 1991.
32. Maniatis, T, Fritsh, E. F., and Sambrook, J. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1982.
33. Cascino, I., Papoff, G., De Maria, R., Testi, R., and Ruberti, G. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol., 156: 13-17, 1996.
34. Long, E. O., Rosen, B-S., Karp, D. R., Malnati, M., Sekaly, R. P., and Jaraquemada, D. Efficient cDNA expression vectors for stable and transient expression of HLA-DR in transfected fibroblast and lymphoid cells. Hum. Immunol., 31: 229-237, 1991.
35. Hostager, B. S., Hsing, Y., Harms, D. E., and Bishop, G. A. Different CD40-mediated signaling events require distinct CD40 structural features. J. Immunol., 157: 1047-1053, 1996.
36. Bishop, G. A., and Frelinger, J. A. Haplotype-specific differences in signaling by transfected class II molecules to a Ly-1+ B-cell clone. Proc. Natl. Acad. Sci. USA, 86: 5933-5937, 1989.
37. Leithauser, F., Dhein, J., Mechtersheimer, G., Koretz, K., Bruderlein, S., Henne, C., Schmidt, A., Debatin, K-M., Krammer, P. H., and Moller, P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest., 69: 415-429, 1993.
38. Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Bar, P. J., and Mountz, J. D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science (Washington DC), 263: 1759-1762, 1994.
39. Cascino, I., Fiucci, G., Papoff, G., and Ruberti, G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol., 154: 2706-2713, 1995.
40. Papoff, G., Cascino, I., Eramo, A., Starace, G., Lynch, D. H., and Ruberti, G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J. Immunol., 156: 4622-4630, 1996.
41. Su, X., Zhou, T., Wang, Z., Yang, P., Jope, R. S., Mountz, J. D. Defective expression of hematopoietic cell protein tyrosine phosphatase (HCP) in lymphoid cells blocks Fas-mediated apoptosis. Immunity, 2: 353-362, 1995.
42. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
43. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human box gene. Cell, 80: 293-299, 1995.
44. Isaacs, W. B., Carter, B. S., and Ewing, C. M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res., 51: 4716-4720, 1991.
45. Carrol, A. G., Voeller, H. J., Sugars, L., and Gelmann, E. P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate, 23: 123-134, 1993.
46. Haldar, S., Chintapalli, J., and Croce, C. M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 56: 1253-1255, 1996.
47. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Sameshima, S-I., Hase, A., Seto, Y., and Nagata, S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66: 233-243, 1991.
48. Banchereau, J., Bazan, F., Blanchard, D., Briere, F., Galizzi, J. P., van Kooten, C., Liu, Y. J., Rousset, F., and Saeland, S. The CD40 antigen and its ligand. Annu. Rev. Immunol., 12: 881-922, 1994.
49. Cleary, A. M., Fortune, S. M., Yellin, M. J., Chess, L., and Lederman, S. Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells. J. Immunol., 155: 3329-3337, 1995.
50. Hess, S., and Engelmann, H. A novel function of CD40: induction of cell death in transformed cells. J. Exp. Med., 183: 159-167, 1996.
51. Raghavan, D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin. Oncol., 15: 371-389, 1988.
52. Takeuchi, T., Sasaki, Y., Ueki, T., Kaziwara, T., Moriyama, N., Kawabe, K., and Kakizoe, T. Modulation of growth and apoptosis response in PC-3 and LNCaP prostate-cancer cell lines by Fas. Int. J. Cancer, 67: 709-714, 1996.
53. Yang, E., and Korsmeyer, S. J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood, 88: 386-401, 1996.
54. Raffo, A. J., Perlman, H., Chen, M-W., Day, M. L., Streitman, J. S., and Buttyan, R. Overexpression of bc1-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55: 4438-4445, 1995.